Use: Labeled indications
- Olopatadine hydrochloride ophthalmic solution USP, 0.2 % is indicated for the treatment of ocular itching associated with allergic conjunctivitis.
Full indications and usage US FDA label
1 INDICATIONSAND USAGE Olopatadine hydrochloride ophthalmic solution USP, 0.2 % is indicated for the treatment of ocular itching associated with allergic conjunctivitis. Olopatadine hydrochloride ophthalmic solution USP, 0.2 % is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.
Contraindications
4 CONTRAINDICATIONS None.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION The recommended dose is one drop in each affected eye once a day. The recommended dose is one drop in each affected eye once a day.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Ophthalmic solution: 1 mg/mL
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Olopatadine as as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Optihist-PatOlopatadine (as hydrochloride | 1mg/ml (0.1% w/v) Ophthalmic Solution (Eye Drops)Low Density Polyethylene (LDPE) white opaque plastic droptainer container and nozzle with High Density Polyethylene (HDPE) screw cap x 5 mL (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Ensight Pharmaceuticals Inc. | DRP-13047 | Nov 22, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution 0.2%: each ml contains 2.22 mg of olopatadine hydrochloride. Ophthalmic solution 0.2%: each ml contains 2.22 mg of olopatadine hydrochloride.
Warnings/Precautions
5.1 For
5.1 For topical ocular use only. Not for injection or oral use.
5.2 Contamination of Tip and Solution
5.2 Contamination of Tip and Solution As with any eye drop, to prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.
5.3 Contact Lens Use
5.3 Contact Lens Use Patients should be advised not to wear a contact lens if their eye is red. Olopatadine hydrochloride ophthalmic solution USP, 0.2% should not be used to treat contact lens related irritation. The preservative in Olopatadine hydrochloride ophthalmic solution USP 0.2%, benzalkonium chloride, may be absorbed by soft contact lenses.
Patients who wear soft contact lenses and whose eyes are not red, should be instructed to wait at least ten minutes after instilling olopatadine hydrochloride ophthalmic solution USP, 0.2% before they insert their contact lenses. For topical ocular use only. Not for injection or oral use (5.1).
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS Symptoms similar to cold syndrome and pharyngitis were reported at an incidence of approximately 10%. The following adverse experiences have been reported in 5% or less of patients: Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion. Some of these events were similar to the underlying disease being studied. Symptoms similar to cold syndrome and pharyngitis were reported at an incidence of approximately 10%. (6) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceutical Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Teratogenic effects: Pregnancy Category C Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 150,000 times the MROHD and rabbits treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during organogenesis showed a decrease in live fetuses.
In addition, rats treated with 600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal weight. Further, rats treated with 600 mg/kg/day of olopatadine during late gestation through the lactation period showed a decrease in neonatal survival and body weight. There are, however, no adequate and well- controlled studies in pregnant women.
Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.
Breastfeeding considerations
Lactation (US label) US FDA label
8.3 Nursing Mothers Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when olopatadine hydrochloride ophthalmic solution USP, 0.2% is administered to a nursing mother.
Mechanism of action
12.1 Mechanism of Action Olopatadine is a mast cell stabilizer and a histamine H1 antagonist. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
US FDA labelPharmacokinetics
The elimination half-life in plasma following oral dosing was 8 to 12 hours, and elimination was predominantly through renal excretion.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Systemic bioavailability data upon topical ocular administration of olopatadine hydrochloride ophthalmic solution USP, 0.2% are not available. Following topical ocular administration of olopatadine 0.15% ophthalmic solution in man, olopatadine was shown to have a low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (< 0.5 ng/mL).
Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The elimination half-life in plasma following oral dosing was 8 to 12 hours, and elimination was predominantly through renal excretion. Approximately 60 – 70 % of the dose was recovered in the urine as parent drug.
Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. OLOPATADINE HYDROCHLORIDE · Alembic Pharmaceuticals Inc. [US FDA-approved label, version 4, May 7, 2019]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbcdf10c-5adb-4d48-97ce-f4b82c6bc77d
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .